First-in-class Advantage Leverage spevatamig and peluntamig as first-in-class bispecific antibodies with FDA orphan drug and Fast Track designations to target high-need oncology indications, presenting a compelling value proposition for partnerships and licensing deals.

PDAC Focus Prioritize collaboration opportunities around metastatic pancreatic ductal adenocarcinoma given the Phase 2 frontline chemo combination results for spevatamig, the ongoing trials, and the potential to expand to claudin 18.2-positive tumors.

Strategic Collaborations Explore BD partnerships with major pharma players (e.g., Merck/MSD collaboration history) to co-develop spevatamig with pembrolizumab, signaling a proven path for combination regimens and larger-scale trials.

Pipeline Leverage Capitalize on Phanes proprietary platforms PACbody SPECpair and ATACCbody to position the company as a source of novel biologics for oncology, enabling joint development or in-licensing discussions around next-generation bsAbs.

Clinical Momentum Highlight ongoing enrollment milestones and positive Phase 2 results at major conferences like ASCO to stimulate investor interest and create timely opportunities for strategic sponsorships, co-promotion, or financing collaborations to accelerate late-stage development.